Chat with us, powered by LiveChat

News & Events


July 25, 2018

Poster Presentation Accepted To The international Congress On In Vitro Toxicology 

“An integrated Human organ system for evaluating cholestasis” accepted as poster presentation for the 20th International congress on In Vitro Toxicology from 15- 18 October 2018 Berlin, Germany. 


June 25, 2018

IONTOX To Attend EuroTox 2018

Stop by the IONTOX booth at EUROTOX 2018 to learn about the company’s latest developments in applied in vitro technology including a mesoscale multiple-organ in vitro test platform, HuDMOPTM.


June 20 2018

Dr. Jamin Willoughby Presents Poster At The International Council of Chemistry Associations-Long Ranger Research Initiative (ICCA-LRI)

Dr. Jamin Willoughby presents poster at the International Council of Chemistry Associations-Long Range Research Initiative (ICCA-LRI) in Ottawa, Ontario. 


March 30 2018

IONTOX And MatTek Corp. Announce Joint Webinar On The Human Dynamic Multiple Organ Plate. 

MatTek Corp. and IONTOX, LLC Team up for a one hour webinar on Modeling Gut-Liver Interaction Using EpiIntestinal™ Micro-Tissues In the Human Dynamic Multi-Organ Plate (Hu-DMOP™).


April 6, 2018

IONTOX Booth Confirmed For The ACT 2018 In West Palm Beach

On April 6th, IONTOX Vice President of New Business Development & Marketing, Maryam Famourzadeh, received confirmation of IONTOX’s booth acceptance for the 39th annual meeting of the American College of Toxicology. 


March 12, 2018

IONTOX President Dr. James Mckim Is Slated As Keynote Speaker During SOT Workshop On Predicting Drug-Induced Cholestatic Liver Injury. 

Drug-induced liver injury is a major reason of failure during premarketing and postmarketing phases of drug development. Being responsible for more than 50% of all cases of acute liver failure worldwide, drug-induced liver injury is equally of high clinical concern.


February 2, 2018

IONTOX Announces The Company Can Screen 100 Compounds In Under A Week With The Glu/Gal Assay.

In early 2017 IONTOX trade marked a new service, FastTox™, offering a 100 compound Adenosine Triphosphate (ATP) screen in under a week. This service is now extended to cover questions related to xenobiotic-induced mitochondrial impairment with the Glucose / Galactose assay (Glu/Gal) using the HepG2 (ATCC HB-8065) cell-line. 


January 26, 2018

Astronaut Joe Acaba Says IONTOX Joint Project Is Most Exciting Project On Board The ISS

In January astronaut Joe Acaba was asked, “What is the most exciting project on board the ISS and what is the ultimate goal of that project?.” He responded, “Just recently I was working on an experiment that was looking at bone cells [osteoblasts] and adding a chemical to the bone cells that would help heal bone.”


January 22, 2018

MSU & IONTOX Announce Joint Webinar On A New Assay To Predict Idiosyncratic Drug Induced Liver Injury.  

IDILI-ROC assay co-developer, Dr. Robert Roth, Ph.D., DABT, Professor of Pharmacology and Toxicology at MSU and IONTOX announce a one hour webinar on predicting IDILI in vitro slated for February 28th.


November 11, 2017

IONTOX Announces The Company’s First Webinar On The Human Dynamic Multiple Organ Plate.

IONTOX announces the first webinar on the company’s proprietary technology slated for December 6th, 2018. 


September 5, 2017

Dr. James Mckim To Speak at the Hepatocyte Expert Program In San Diego. 

A presentation, done in conjunction with Qualyst Transporter Solutions, which shed light on the failures of existing hepatic models, and how new models can greatly enhance an organizations ability to understand how both their compound effects cholestasis.


October 30, 2017

LaunchPad Medical, LLC & IONTOX Announce Collaboration To Study The Effects Of Micro Gravity On Osteoblasts In Space. 

 IONTOX, LLC is to participate in a novel investigation of the effects of microgravity on bone cell growth aboard the International Space Station (ISS). 


August 24th, 2017

IONTOX President Gives Oral Presentation At The 10th World Congress On Alternatives And Animals in The Life Sciences With Qualyst Transporter Solutions.  

On Thursday, August 24th at 10:00 AM IONTOX president Jim Mckim, gave an oral presentation at the 10th World Congress on Alternatives and Animals in the Life Sciences along side Qualyst Transporter Solutions on new methods for predicting drug-induced liver toxicity and integrated multiple organ test systems.


August 20th, 2017

IONTOX & MSU Enter Into Exclusive Licenses To Offer New Assay To Predict IDILI liability In Vitro

A presentation, done in conjunction with Qualyst Transporter Solutions, which promises to shed light on the failures of existing hepatic models, and how new models can greatly enhance an organizations ability to understand how both their compound effects cholestasis.


February 27th, 2017

IONTOX President Dr. Jim Mckim & Director of Laboratory Operations Nick Hibbard Announce Participation In SOT 2017

From Saturday, March 11th to March 15th IONTOX founder Toxicologist Jim Mckim and Director of Laboratory Operations Nick Hibbard will be at the Annual Society of Toxicology meeting in Baltimore, Maryland.


November 24, 2016

IONTOX And British American Tobacco Announce Collaboration To Develop Lung Liver Lung Model In Vitro.  

IONTOX and British American Tobacco collaborate to develop a multiple organ plate consisting of a human lung model linked to a human liver model to investigate what chemicals are passed from the lung to the liver and then back to the lung following exposure.  


November 16, 2016

IONTOX Representative Attends National Organic Saftey Board Meeting To Discuss Carrageenan Safety  

On Wednesday, November 16, 2016, IONTOX President, James McKim attended a meeting of the National Organic Standards Board (NOSB) in St. Louis to discuss the safety of the commonly used food additive carrageenan.